BRPI1006651A2 - Medicamentos anticancer e usos relacionados para melanome maligno e outros canceres - Google Patents

Medicamentos anticancer e usos relacionados para melanome maligno e outros canceres

Info

Publication number
BRPI1006651A2
BRPI1006651A2 BRPI1006651-9A BRPI1006651A BRPI1006651A2 BR PI1006651 A2 BRPI1006651 A2 BR PI1006651A2 BR PI1006651 A BRPI1006651 A BR PI1006651A BR PI1006651 A2 BRPI1006651 A2 BR PI1006651A2
Authority
BR
Brazil
Prior art keywords
melanome
cancers
malignant
related uses
anticancer medicines
Prior art date
Application number
BRPI1006651-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Kasina
Sudhakar
Somepalli
Venkateswarlu
Bhupathiraju
Kiran
Gokaraju Rama Raju
Golakoti
Trimurtulu
Gokaraju
Venkata
Kanaka
Ranga
Raju
Alluri
Krishna
Ganga
Sengupta
Krishanu
Original Assignee
Kasina Laila Innova Pharmaceuticals Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kasina Laila Innova Pharmaceuticals Private Ltd filed Critical Kasina Laila Innova Pharmaceuticals Private Ltd
Publication of BRPI1006651A2 publication Critical patent/BRPI1006651A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/04—1,2,3-Triazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D517/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains three hetero rings
    • C07D517/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI1006651-9A 2009-04-27 2010-04-26 Medicamentos anticancer e usos relacionados para melanome maligno e outros canceres BRPI1006651A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN959CH2009 2009-04-27
PCT/IN2010/000262 WO2010125575A1 (en) 2009-04-27 2010-04-26 Anti-cancer drugs, and uses relating for malignant melanoma and other cancers

Publications (1)

Publication Number Publication Date
BRPI1006651A2 true BRPI1006651A2 (pt) 2015-08-25

Family

ID=42992332

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006651-9A BRPI1006651A2 (pt) 2009-04-27 2010-04-26 Medicamentos anticancer e usos relacionados para melanome maligno e outros canceres

Country Status (11)

Country Link
US (1) US8143237B2 (enExample)
EP (1) EP2424351B1 (enExample)
JP (1) JP5571168B2 (enExample)
KR (1) KR20120006554A (enExample)
CN (1) CN102438449B (enExample)
AU (1) AU2010243213B2 (enExample)
BR (1) BRPI1006651A2 (enExample)
CA (1) CA2759519A1 (enExample)
IL (1) IL215789A0 (enExample)
NZ (1) NZ595602A (enExample)
WO (1) WO2010125575A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
CN103221048A (zh) 2010-11-18 2013-07-24 卡斯纳莱拉创新药物私人有限公司 取代的4-(硒吩-2(或3)-基氨基)嘧啶化合物及其使用方法
AU2011340063B2 (en) * 2010-12-09 2016-03-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
WO2012176212A1 (en) 2011-06-20 2012-12-27 V.B. Medicare Pvt. Ltd. Carrier based nanogel formulation for skin targeting.
KR101418776B1 (ko) 2011-09-28 2014-07-14 사회복지법인 삼성생명공익재단 셀레노펜-접합 방향족 화합물, 및 이의 제조 방법
CN103906742A (zh) * 2011-09-28 2014-07-02 世宗大学校产学协力团 硒吩稠合芳族化合物和其制备方法
WO2014012074A2 (en) 2012-07-12 2014-01-16 Euclises Pharmaceuticals, Inc. No-releasing nonoate (nitrogen-bound) sulfonamide-linked-coxib anti-cancer agents
US9044464B2 (en) 2012-07-12 2015-06-02 Euclises Pharmaceuticals, Inc. No-releasing guanidine-coxib anti-cancer agents
US9505765B2 (en) 2012-07-26 2016-11-29 Confluence Life Sciences Inc. 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment
US20140199728A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
WO2016118951A2 (en) 2015-01-23 2016-07-28 Confluence Life Sciences, Inc. Heterocyclic itk inhibitors for treating inflammation and cancer
CN108129475A (zh) * 2018-02-08 2018-06-08 中南大学湘雅三医院 一种生物光敏剂及其制备方法和应用
KR102648781B1 (ko) 2021-11-09 2024-03-19 국립공주대학교 산학협력단 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도
WO2025005748A1 (ko) * 2023-06-29 2025-01-02 (주)아이젠사이언스 신규 셀레노펜 유도체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620804B2 (en) * 1996-06-03 2003-09-16 Purdue Research Foundation Selenophene anti-tumor agents
DE69724472T2 (de) * 1996-06-03 2004-06-17 Purdue Research Foundation, West Lafayette Selenophen-antitumormittel
WO2008016664A2 (en) * 2006-08-02 2008-02-07 University Of Massachusetts Lowell Compositions and methods for treating cancer with dacarbazine nanoemulsions
WO2010029577A2 (en) * 2008-09-15 2010-03-18 Ganga Raju Gokaraju Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Also Published As

Publication number Publication date
CN102438449B (zh) 2014-06-18
EP2424351A1 (en) 2012-03-07
EP2424351A4 (en) 2013-04-03
AU2010243213A1 (en) 2011-10-27
JP2012525329A (ja) 2012-10-22
US8143237B2 (en) 2012-03-27
CA2759519A1 (en) 2010-11-04
AU2010243213B2 (en) 2014-09-11
JP5571168B2 (ja) 2014-08-13
NZ595602A (en) 2013-05-31
US20100272678A1 (en) 2010-10-28
KR20120006554A (ko) 2012-01-18
CN102438449A (zh) 2012-05-02
WO2010125575A1 (en) 2010-11-04
IL215789A0 (en) 2012-01-31
EP2424351B1 (en) 2015-10-21
HK1166591A1 (en) 2012-11-02

Similar Documents

Publication Publication Date Title
BRPI1006651A2 (pt) Medicamentos anticancer e usos relacionados para melanome maligno e outros canceres
HUS2300018I1 (hu) Rákellenes hatású kinoli-8-szulfonamid-származékok
BRPI0913485A2 (pt) medicamentos anticâncer e usos relacionados para melanoma maligno metastático e outros cânceres.
BR112015007866A2 (pt) combinação de opióides e fármacos anticancerígenos para o tratamento do câncer.
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
ES2638522T8 (es) Procedimientos para detectar cáncer
BR112012011902A2 (pt) cápsula farmacêutica
PT2768493T (pt) Fitocanabinoides para utilização no tratamento do cancro da mama
PT3195873T (pt) Nova imunoterapia para vários tumores, incluindo cancro gastrointestinal e gástrico
EP2836216A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER
IL220386B (en) Compositions for the liquidation of tumors and uses thereof
PT2162149E (pt) Vacina para a prevenção da recaída do cancro da mama
BRPI1006438A2 (pt) terapia adjuvante de cancer
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
GB201016139D0 (en) Cancer phosholipidome
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
BRPI0924981A2 (pt) vacinas para câncer cervical.
BRPI1010874A8 (pt) composição para o tratamento de câncer de próstata
SMT201700056B (it) Fosfaplatine e relativo utilizzo per il trattamento di cancro
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
EP2575887A4 (en) CONJUGATES OF OPTIMIZED MEDICINES
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
BRPI0922653A2 (pt) preparação farmacêutica
EP2606137A4 (en) ANTI-CANCER ADENOVIRUSES
BRPI1011206A2 (pt) administração contínua de ligantes de integrina para tratar câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]